This Company Will Work With Nonprofit Organizations to Develop New Treatment for Epidermolysis Bullosa
<a href="https://pixabay.com/users/DarkoStojanovic/">DarkoStojanovic</a> / Pixabay

This Company Will Work With Nonprofit Organizations to Develop New Treatment for Epidermolysis Bullosa

According to a story from PR Newswire, the biopharmaceutical company Constant Pharmaceuticals recently announced that it plans to develop its experimental compound TXA127 as a therapy for epidermolysis bullosa (EB).…

Continue Reading
  • 1
  • 2
Close Menu